Drug Trial Radar · NCT04616586
SILtuximab in Viral ARds (SILVAR) Study
Last checked: Nov 20, 2026Latest source record: Apr 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
555
Actual
Start
Nov 13, 2020
Primary completion
Apr 1, 2021
Study completion Apr 1, 2021
Sponsor
- Lead sponsor
- RECORDATI GROUPIndustry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Nov 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.
Conditions
- Acute Respiratory Distress Syndrome
- Lung Diseases
- Pneumonia
- Respiratory Tract Infections
- Respiratory Tract Disease
Interventions
SiltuximabDrug
11 mg/kg IV administered over 1 hour
Normal SalineOther
IV administered over 1 hour
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28-day all-cause mortalityTime frame: Day 28
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sparrow Clinical Research Institute
Lansing, Michigan
Atrium Health
Charlotte, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.